Source:http://linkedlifedata.com/resource/pubmed/id/12406823
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
2002-11-7
|
| pubmed:abstractText |
The aim of this double-blind single center study (the COPE study) was to investigate the effect of discontinuation of the inhaled corticosteroid fluticasone propionate (FP) on exacerbations and health-related quality of life in patients with chronic obstructive pulmonary disease. After 4 months of treatment with FP (1,000 microg/day), 244 patients were randomized to either continue FP or to receive placebo for 6 months: 123 patients continued FP (FP group), and 121 received placebo (placebo group). In the FP group, 58 (47%) patients developed at least one exacerbation compared with 69 (57%) in the placebo group. The hazard ratio of a first exacerbation in the placebo group compared with the FP group was 1.5 (95% confidence interval [CI] 1.1-2.1). In the placebo group 26 patients (21.5%) experienced rapid recurrent exacerbations and were subsequently unblinded and prescribed FP compared with 6 patients (4.9%) in the FP group (relative risk = 4.4; 95% CI 1.9-10.3). Over a 6-month period, a significant difference in favor of the FP group was observed in the total score (+2.48 95% CI 0.37-4.58), activity domain (+4.64 95% CI 1.60-7.68), and symptom domain (+4.58 95% CI 1.05-8.10) of the St. George's Respiratory Questionnaire. This study indicates that discontinuation of FP in patients with chronic obstructive pulmonary disease is associated with a more rapid onset and higher recurrence-risk of exacerbations and a significant deterioration in aspects of Health-Related Quality of Life.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
1073-449X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
166
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1358-63
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:12406823-Administration, Inhalation,
pubmed-meshheading:12406823-Adrenal Cortex Hormones,
pubmed-meshheading:12406823-Adult,
pubmed-meshheading:12406823-Aged,
pubmed-meshheading:12406823-Androstadienes,
pubmed-meshheading:12406823-Double-Blind Method,
pubmed-meshheading:12406823-Exercise Tolerance,
pubmed-meshheading:12406823-Female,
pubmed-meshheading:12406823-Follow-Up Studies,
pubmed-meshheading:12406823-Forced Expiratory Volume,
pubmed-meshheading:12406823-Humans,
pubmed-meshheading:12406823-Lung,
pubmed-meshheading:12406823-Male,
pubmed-meshheading:12406823-Middle Aged,
pubmed-meshheading:12406823-Pulmonary Disease, Chronic Obstructive,
pubmed-meshheading:12406823-Quality of Life,
pubmed-meshheading:12406823-Recurrence,
pubmed-meshheading:12406823-Severity of Illness Index,
pubmed-meshheading:12406823-Smoking,
pubmed-meshheading:12406823-Substance Withdrawal Syndrome,
pubmed-meshheading:12406823-Treatment Outcome
|
| pubmed:year |
2002
|
| pubmed:articleTitle |
Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study.
|
| pubmed:affiliation |
Department of Pulmonary Medicine, Medisch Spectrum Twente, Enschede, The Netherlands. valkpapa@knmg.nl
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|